Anti‐cytokine, all‐cause mortality ‐ low risk of bias studies · patients with sepsis, severe sepsis, septic shock
Monoclonal antibodies leads to lower anti‐cytokine, all‐cause mortality ‐ low risk of bias studies compared with placebo (high certainty).
1 finding from 1 review
All‐cause mortality ‐ sensitivity analysis · patients with sepsis, severe sepsis, septic shock
Monoclonal antibodies showed no clear difference in anti‐endotoxin, all‐cause mortality ‐ low risk of bias studies compared with placebo (moderate certainty).
1 finding from 1 review
28‐Day all cause mortality (adult studies) · adult patients with sepsis, severe sepsis and septic shock
Polyclonal intravenous immunoglobulin (IVIG) showed no clear difference in low risk of bias adult studies, by type of polyclonal IVIG,… compared with placebo or no intervention (high certainty).
3 findings from 1 review
RR 0.97 [0.81, 1.15]
5 studies · 945 participants
High
RR 1.02 [0.84, 1.24]
3 studies · 683 participants
High
RR 0.82 [0.56, 1.19]
2 studies · 262 participants
Moderate
All‐cause mortality, neonates, standard polyclonal IVIG · neonates with sepsis, severe sepsis and septic shock
Polyclonal intravenous immunoglobulin (IVIG) showed no clear difference in low risk of bias neonate studies, mortality all‐cause ‐ standard IVIG compared with placebo or no intervention (high certainty).
1 finding from 1 review
Subgroup analysis of longer‐term mortality: lower tidal volume ventilationAlive or dead · adults with acute respiratory failure
Mortality: prone position probably leads to lower subgroup analysis of longer‐term mortality: lower tidal volume… compared with supine (moderate certainty).
1 finding from 1 review
Mortality before hospital discharge · patients with ALI and ARDS
High levels of PEEP showed no clear difference in mortality before hospital discharge compared with low levels of PEEP (moderate certainty).
1 finding from 1 review
All‐cause mortality: range 1 mo to 1 y · adults admitted to the ICU
It is very uncertain whether higher changes all‐cause mortality: range 1 mo to 1 y compared with lower FiO2 or targets of arterial oxygenation (very low certainty).
1 finding from 1 review
All‐cause mortality · people hospitalised with COVID‐19
Higher‐dose anticoagulants showed no clear difference in all‐cause mortality compared with lower‐dose anticoagulants (high certainty).
1 finding from 1 review
Mortality related to COVID‐19 · people hospitalised with COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Other adverse events Non‐mortality · adult survivors of critical illness
1 finding from 1 review
Intervention not reported
Mortality Death at any point during the trial duration · adult survivors of critical illness
1 finding from 1 review
In‐hospital mortality (up to 90 days; included studies reported in‐hospital mortality, and mortality up to 28 days and up to ICU discharge) · adults in the ICU, requiring respiratory support
HFNC showed no clear difference in in‐hospital mortality (up to 90 days; included studies reported… compared with NIPPV or NIV (low certainty).
1 finding from 1 review
In‐hospital mortality (up to 90 days; included studies reported in‐hospital mortality, and mortality up to 28 days and up to ICU discharge) · adults in the ICU, requiring respiratory support
HFNC showed no clear difference in in‐hospital mortality (up to 90 days; included studies reported… compared with standard oxygen therapy (moderate certainty).
1 finding from 1 review